Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I‐BFM analysis of 333 children. (3rd February 2020)

• Record Type: Journal Article
• Authors: Uden, Theodor; Bertaina, Alice; Abrahamsson, Jonas; Ansari, Marc; Balduzzi, Adriana; Bourquin, Jean‐Pierre; Gerhardt, Corinne; Bierings, Marc; Hasle, Henrik; Lankester, Arjan; Mischke, Kirsten; Moore, Andrew S.; Nivison‐Smith, Ian; Pieczonka, Anna; Peters, Christina; Sedlacek, Petr; Reinhardt, Dirk; Stein, Jerry; Versluys, Birgitta; Wachowiak, Jacek; Willems, Leen; Zimmermann, Martin; Locatelli, Franco; Sauer, Martin G.
• Is Part Of: British journal of haematology. Volume 189:Number 4(2020)
• Page Start: 745
• Page End: 750
• Publication Date: 2020-02-03
• Subjects: allogeneic hematopoietic stem cell transplantation -- children -- relapse -- acute myeloid leukemia -- second hematopoietic stem cell transplantation; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16441
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four‐year probability of overall survival (4y‐pOS) was 14%. 4y‐pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not ( P = <0·0001). Achievement of a subsequent remission impacted survival ( P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non‐relapse mortality at four years reached 45% and 22%.